Cumulative exposure to phthalates from phthalate-containing drug products: A Danish population-wide study

Aims Up to 50‐fold higher levels of urinary phthalate metabolites have been observed in users of phthalate‐containing drug products compared with non‐users. This is of concern, as phthalates are suspected endocrine disrupters and have been associated with cancer development. This study aims to quantify annual cumulated phthalate exposure from drug products among users of phthalate‐containing oral medications in Denmark throughout the period of 2004–2016.